ArticleSkin health and disease2025
Unravelling the challenges of mycetoma: a case series highlighting diagnostic dilemmas and therapeutic triumphs.
Article in Skin health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycetoma is a chronic suppurative granulomatous infection of the deep dermis and subcutaneous tissue prevalent in tropical and subtropical regions and is caused by filamentous aerobic bacteria (actinomycetoma) or true fungi (eumycetoma), representing 60% and 40% of cases worldwide, respectively. The causative organism enters into the subcutaneous tissue, usually of the foot, from contaminated soil or vegetative material through inoculation from a thorn prick, or repeated trauma. It commonly affects men, farmers and field workers. Differentiating eumycetoma from actinomycetoma can be challenging but is required before starting prolonged treatment. One of our patients presented with lesions on the thigh and in a sporotrichoid pattern that is atypical, while the other two patients were treated with antifungal medication for eumycetoma for years without proper investigation and improvement. Early diagnosis of actinomycetoma is mandatory to prevent tissue destruction, bone invasion and ultimate loss of function by proper investigative workup, histopathology and direct microscopy of discharge. We here report three cases of actinomycetoma with clinical and microbiology profiles treated successfully with tablets of trimethoprim-sulfamethoxazoleand amoxicillin-clavulanic acid along with folic acid as proposed by the Cochrane systemic review protocol 2018.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.